Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upneeq in Acquired Blepharoptosis
NCT03565887Phase 3Completed
- Sponsor
- RVL Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acquired blepharoptosis comparing Upneeq with Placebo (2 arms). Primary endpoint: Mean Change in Number of Points Seen on the Leicester Peripheral Field Test. Started Jun 2018; status: completed.
02
Drugs
oxymetazoline
03
Conditions
acquired blepharoptosis
Beyond the preview
Go deeper on NCT03565887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03565887.